Pedro Huertas, MD, PhD
Chief Medical Officer
Dr. Huertas has nearly 30 years of pharmaceutical industry experience in research and development, medical affairs and regulatory affairs in therapeutics for human genetic and metabolic diseases. Prior to joining Sentien, Dr. Huertas was Chief Medical Officer for Eloxx Pharmaceuticals, a company focused on rare and ultra-rare genetic diseases. His prior experience includes positions at Pfizer, Shire, Genzyme, Amicus Therapeutics, Novazyme, Advanced Cell Technology and StemCells, Inc. Dr. Huertas is a graduate of Stanford University (MS, Biochemistry), Harvard University (PhD, Cell and Developmental Biology), Harvard Medical School (MD), and MIT Sloan School of Management (MS, Management). He also trained in Internal Medicine, Rheumatology and Palliative Care at Massachusetts General Hospital.